SI0632129T1 - Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors - Google Patents

Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors

Info

Publication number
SI0632129T1
SI0632129T1 SI9430447T SI9430447T SI0632129T1 SI 0632129 T1 SI0632129 T1 SI 0632129T1 SI 9430447 T SI9430447 T SI 9430447T SI 9430447 T SI9430447 T SI 9430447T SI 0632129 T1 SI0632129 T1 SI 0632129T1
Authority
SI
Slovenia
Prior art keywords
foamy virus
virus vectors
recombinant foamy
medicinal
processes
Prior art date
Application number
SI9430447T
Other languages
English (en)
Slovenian (sl)
Inventor
Meulen Volker Prof.Dr. ter
Axel Dr. Rethwilm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SI0632129T1 publication Critical patent/SI0632129T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/17043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
    • C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
SI9430447T 1993-06-03 1994-05-24 Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors SI0632129T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4318387A DE4318387A1 (de) 1993-06-03 1993-06-03 Rekombinante Foamy Virus Vektoren für medizinische und diagnostische Anwendungen sowie Verfahren zur Herstellung von rekombinanten Foamy Virus Vektoren
EP94107918A EP0632129B1 (en) 1993-06-03 1994-05-24 Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors

Publications (1)

Publication Number Publication Date
SI0632129T1 true SI0632129T1 (en) 2003-08-31

Family

ID=6489499

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9430447T SI0632129T1 (en) 1993-06-03 1994-05-24 Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors

Country Status (10)

Country Link
US (1) US5646032A (es)
EP (1) EP0632129B1 (es)
JP (2) JPH06343477A (es)
AT (1) ATE237693T1 (es)
CA (1) CA2124769C (es)
DE (2) DE4318387A1 (es)
DK (1) DK0632129T3 (es)
ES (1) ES2196014T3 (es)
PT (1) PT632129E (es)
SI (1) SI0632129T1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
FR2727429B1 (fr) 1994-11-30 1997-11-28 Haguenauer Odile Cohen Lignees d'encapsidation et vecteurs d'expression pour la transcomplementation de vecteurs retroviraux defectifs
DE19503082A1 (de) 1995-02-01 1996-08-08 Univ Ludwigs Albert Gegenstand und Verfahren zur bevorzugt transienten Expression und möglichen Translation spezifischer RNA im cytoplasmatischen Bereich höherer eukaryontischer Zellen
US5888767A (en) * 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
CA2279669A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
US6492165B1 (en) 1997-02-12 2002-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retrovirus isolated from humans
US5882912A (en) * 1997-02-12 1999-03-16 Center For Disease Control And Prevention Retrovirus isolated from humans
JP3954151B2 (ja) * 1997-03-14 2007-08-08 トランスジエヌ・エス・アー フォーミーウイルスエンベロープタンパク質の発現
WO2000024876A2 (en) 1998-10-27 2000-05-04 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Spumavirus isolated from humans
DE19858441C2 (de) * 1998-12-17 2001-02-15 Deutsches Krebsforsch FV-Vektoren zur Expression von Fremdgenen in Säugern und deren Verwendung
WO2000041732A1 (en) * 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6800475B1 (en) 1999-06-14 2004-10-05 The United States Of America As Represented By The Department Of Health And Human Services Isolation of a human retrovirus
CA2492131A1 (en) * 2002-06-27 2004-01-08 The Government Of The United States Of America, As Represented By The Se Cretary Department Of Health And Human Services Centers For Disease Cont Live replicating spumavirus vector
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7655772B2 (en) 2002-09-06 2010-02-02 University Of South Florida Materials and methods for treatment of allergic diseases
US20050272650A1 (en) * 2004-02-17 2005-12-08 Mohapatra Shyam S Materials and methods for treatment of inflammatory and cell proliferation disorders
WO2005117947A1 (en) * 2004-06-04 2005-12-15 Deutsches Krebsforschungszentrum - Stiftung Des Öffentlichen Rechts - Use of the foamy virus bet protein for inactivating apobec
CA2656990A1 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
CN111093715A (zh) * 2017-09-18 2020-05-01 儿童医院医疗中心 强绝缘子和其在基因递送中的用途

Also Published As

Publication number Publication date
US5646032A (en) 1997-07-08
JPH06343477A (ja) 1994-12-20
DE69432500D1 (de) 2003-05-22
ATE237693T1 (de) 2003-05-15
CA2124769C (en) 2007-07-10
EP0632129A1 (en) 1995-01-04
DK0632129T3 (da) 2003-08-04
EP0632129B1 (en) 2003-04-16
PT632129E (pt) 2003-08-29
DE69432500T2 (de) 2003-11-20
DE4318387A1 (de) 1994-12-08
JP2007082562A (ja) 2007-04-05
ES2196014T3 (es) 2003-12-16
CA2124769A1 (en) 1994-12-04

Similar Documents

Publication Publication Date Title
SI0632129T1 (en) Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
CA2183151A1 (fr) Systeme hote-vecteur utilisable en therapie genique
AU6663096A (en) Viral vectors and line for gene therapy
DE3586520D1 (de) Herpes simplex-virus als vektor.
CA2072627A1 (en) Recombinant herpes simplex viruses vaccines and methods
AU8067698A (en) Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus
NZ500740A (en) Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
CA2161962A1 (en) Adenovirus vectors for gene therapy
YU233582A (en) Process for the expression of a gene coded for human imunological interferon
EP1923467A3 (en) Adenovirus vectors for gene therapy
EP1683858A3 (en) Viral preparations, vectors, immunogens, and vaccines
AU3970489A (en) Expression cassette for plants
CA2321964A1 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus
WO1998055639A3 (fr) Vecteurs adenoviraux recombinants comprenant une sequence d'epissage
IL88151A (en) Interleukin-7 protein, dna sequences encoding it, its preparation and compositions containing it
ES8802162A1 (es) Un procedimiento para la preparacion de una levadura trans- formada con un plasmido recombinante insertado con el gen del virus de la hepatitis b.
GB8718779D0 (en) Dna sequence & expression vector
CA2215328A1 (en) Novel human cytomegalovirus dna sequences
AU5318496A (en) Adenovirus vectors for gene therapy
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
EP0242220A3 (en) Gene expression system
IL88371A0 (en) Directed integration of genes into a plant genome and recombinant dna,expression vectors and host cells used therefor
AU4334193A (en) Infectious bovine rhinotracheitis virus mutants and vaccines
AU7949991A (en) Cloned n-methylhydantoinase